Pascual F, Ballesta Gómez R, Ruiz JJ, Colom i Farran J, Yébenes M, Casado MA
Complexity of HCV patients attended at addiction setting in Real-World Practice. results from Complexadic Study
The Liver Meeting, AASLD. Boston (EEUU). 10-14 nov 2023
Vargas-Accarino E, Martínez-Campreciós J, Domínguez-Hernández R, Rando-Segura A, Riveiro-Barciela M, Rodríguez-Frías F, Barreira A, Palom A, Casado MA, Esteban R, Buti M
Impact of COVID-19 pandemic in the ReLink-C strategy to search and retrieve lost-to follow-up HCV patients
The Liver Meeting Digital Experience – AASLD. Digital. 12-15 nov 2021
Forns X, Colom J, García-Retortillo M, Quer JC, Lens S, Domínguez-Hernández R, Casado MA, Buti M
Point-Of-Care hepatitis C testing and treating strategy in people who inject drugs in harm reduction and addiction centers for hepatitis C elimination
The Liver Meeting digital experience (AASLD). Virtual 13-16 nov 2020
Marco A, Domínguez-Hernández R, Casado MA
Cost-Effectiveness Analysis of the Treatment for Chronic Hepatitis C in Spanish Prisoners
69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, EEUU. 9-13 nov 2018
Turnes J, Domínguez-Hernández R, Casado MA
Health outcomes and costs associated with the implementation of a national treatment plan for hepatitis C in Spain
68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, EEUU. 20-24 oct 2017
Buti M. Dominguez-Hernandez R, Casado MA
LEDIPASVIR/SOFOSBUVIR (LDV/SOF) Treatment of naïve PATIENTS WITH Mild CHRONIC HEPATITIS c (CHC) GENOTYPE 1 (GT1) compared To PATIENTS WITH SIGNIFICANT FIBROSIS: IS IT a COST-EFFECTIVE therapy?
The Liver Meeting AASLD’s 67th Annual Meeting in Boston, EEUU. 11-15 nov 2016
Turnes J, Oyagüez I, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Solà R, Casado MA, Romero-Gómez M
Cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients
The Liver Meeting, AASLD’s 64th Annual Meeting in Washington, EEUU, 1-5 Noviembre 2013
Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, Casado MA
Cost-effectiveness analysis of telaprevir triple therapy for treatment-naïve patients with chronic hepatitis C based on the combined efficacy of the ADVANCE and OPTIMIZE studies
The Liver Meeting, AASLD’s 64th Annual Meeting in Washington, EEUU, 1-5 Noviembre 2013
Buti M, Brosa M, Casado MA, Rueda M, Esteban R